Thales Reinforces Its eSIM Management Leadership With Google Cloud Certified and Energy Efficient Services
1.3.2023 10:00:00 EET | Business Wire | Press release
Thales, the world leader in eSIM management, supports the growth of eSIM-enabled consumer and industrial devices with Google Cloud expertise. Thales' pioneering Cloud solution combines its own security assets with Google's cloud presence in 200 countries to provide enhanced security, flexibility, and service availability to MNOs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005040/en/
Thales, a global leader in eSIM management. @Thales
Remote eSIM activation, anytime and anywhere
By 2025, the number of eSIM connections is estimated to reach close to 9 billion1. Fuelled by 5G, the growth in connections is the result of increased connectivity of consumer products such as smartphones, tablets and wearables, and numerous industrial devices. With Thales’ eSIM management platform hosted on Google Cloud completed with Thales digital onboarding solutions, MNOs can offer their subscribers the speed, convenience and efficiency of activating subscriptions remotely. Today, Thales is able to meet high demands from hundreds of customers worldwide, including Telefonica, one of the world's largest telco operators and mobile network providers.
The perfect response to MNOs digital transformation and exponential IoT growth
With easy and secure access to Thales services hosted on Google Cloud, mobile operators can respond immediately to surging demand for eSIM activation and offer their subscribers a full digital experience. Such solutions also provide greater scalability as well as resources mutualisation, enabling mobile operators efficiently and rapidly deploy new services. In terms of security, Thales keeps full control, by designing highly secure end-to-end hardware and software, as well as by storing and managing the secret codes in its secure vaults (secret codes are keys used by devices for eSIM activation to securely access mobile networks). This underpins world-class data privacy, sovereign cloud approach and rigorous defence against cyberattacks.
Certified and sustainable
The eSIM usage has become mission-critical to enable a sustainable access to connectivity for the expanding consumer and industrial IoT. Thales’ integration of global GSMA-certified solution protects MNOs against interruptions in any part of the world. MNOs therefore benefit from outstanding disaster recovery, business continuity and improved quality of services.
Google Cloud’s is today one of the most energy efficient clouds2 in the industry and aims to operate entirely on carbon free energy 24/7 and everywhere in the world by 2030.
“ We have been trustfully partnering with Thales for years to address new connectivity challenges and MNO needs with cloud technology. This future-proof solution provides the market with the required flexibility, security, and resilience to meet consumer’s ‘anytime anywhere’ wish, while also addressing new technological requirements. Adding to Google Cloud services, the security aspect brought by Thales and its remote eSIM management leadership, brings relevance and support to MNOs eSIM strategy.” said Amol Phadke, General manager, Global Telecom Industry at Google Cloud
“There is an increasing consumers’ adoption of eSIM enabled phones, wearables and tablets while MNOs are ramping up for the 5G and IoT revolutions. Two years after the announcement of our partnership with Google Cloud, Thales’ pioneering Cloud eSIM solution has reached its full maturity. Our customers can trust us to support them in their eSIM strategy, meeting data privacy regulations as well as protecting them against the most sophisticated cyber threats” said Eva Rudin, VP Mobile Connectivity Solutions at Thales.
1
Counterpoint, eSIM Ecosystem CORE Analysis, May 2022
2
On average, a Google data center is twice as energy efficient as a typical enterprise data center.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations — connectivity, big data, artificial intelligence, cybersecurity and quantum computing — to build a future we can all trust, which is vital to the development of our societies.
The company provides solutions, services and products that help its customers —businesses, organisations and states — in the defence, aeronautics, space, transportation and digital identity and security markets to fulfil their critical missions, by placing humans at the heart of the decision-making process.
Thales has 81,000 employees in 68 countries. In 2021, the Group generated sales of €16.2 billion
PLEASE VISIT
Thales Group
Digital Identity & Security
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005040/en/
Contact information
Thales, Media Relations
Digital Identity and Security
Vanessa Viala
+33 (0)6 07 34 00 34
vanessa.viala@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom